3Albertini J J ,Lyman G H, Cox C,et al. Lymphatic mapping and sentinel node biopsy in the patients with breast cancer[J].J Am Med Assoc ,1996,276(6) :1818.
2Mlhirddin M,Rosato F,Barbot D,et al.Long-term releases of combined modality treatment with 125I implantation for carcinoma of the pancreas.J Radiat Oncol Biol Phys,1992,23(3):305
5Bleyer A. Young adult oncology: the patients and their survival challenges[ J]. CA Cancer J Clin, 2007,57 (4) : 242-255.
6Nicklasson M, Bergman B. Validity, reliability and clini- cal relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting [ J]. Qual Life Res, 2007,16(6) :1019-1028.
7Wan C H, Tang X L, Tu X M, et al. Psychometric prop- erties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients[ J ]. Breast Cancer Res Treat, 2007,105 ( 2 ) : 187-193.
8Golden-Kreutz D M, Thornton L M, Wells-Di G S, et al. Traumatic stress, perceived global stress, and life events: prospectively predicting quality of life in breast cancer patients [ J ]. Health Psychol, 2005,24 ( 3 ) : 288- 296.
9Maringwa J T, Quinten C, King M, et al. Minimal im- portant differences for nterpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer pa- tients participating in randomized controlled trials [ J]. Support Care Cancer, 2011,19(11) :1753-1760.
10Selby D, Chakraborty A, Myers J, et al. High scores on the Edmonton symptom assessment scale identify patients with self-defined high symptom burden [ J ]. J Palliat Med, 2011,14(12) :1309-1316.
